Why HeartBeam (BEAT) stock jumped on an FDA Breakthrough Device designation for heart attack assessment

HeartBeam (Nasdaq: BEAT) announced before the regular session on Monday, October 5, 2026 that the FDA had granted Breakthrough Device designation to the HeartBeam System as a tool for assessing possible heart attacks at home. BEAT traded at 0.4154 two minutes before our headline crossed at 8:31 a.m. ET, rose 15.70% in the first minute and stood at 0.4989 ten minutes after the headline, up 20.10%.

What HeartBeam's Breakthrough Device designation for heart attacks does

The designation comes from the FDA's Breakthrough Devices Program, which covers devices that may offer more effective diagnosis or treatment of life-threatening or irreversibly debilitating conditions. According to the FDA's program description, designated sponsors get more frequent and interactive contact with agency staff, including "sprint" discussions meant to settle a single development question quickly, and prioritized review once they file a marketing submission. The statutory standard stays the same. A designated device still needs 510(k) clearance, De Novo authorization or premarket approval on the usual evidence before it can be marketed for the new use.

HeartBeam said the FDA granted the designation within 30 days of its request, ahead of the agency's 60-day statutory review period. The company said the designation was supported by proof-of-concept data presented at the American Heart Association's 2025 Scientific Sessions and by the ALIGN-ACS pilot study, which enrolled 134 patients with chest pain at two emergency departments in Belgrade, Serbia, and compared readings from the HeartBeam device and a standard 12-lead ECG against each patient's diagnosis at discharge. HeartBeam had said full ALIGN-ACS results would be presented at the TCT 2026 meeting in San Diego, October 31 to November 3, 2026. It said it expected to seek FDA alignment on the design of a multicenter pivotal study in the coming months and to begin enrollment shortly after, with the study intended to support a future submission adding heart attack assessment to the system's indications.

A heart attack indication HeartBeam has sought since 2022

As of October 5, 2026, HeartBeam's FDA clearances covered arrhythmia assessment only. Its regulatory record on heart attack detection runs back four years:

1. August 16, 2022: HeartBeam submitted a 510(k) for HeartBeam AIMI, software meant to help emergency department physicians detect a heart attack by comparing a patient's baseline and symptomatic 12-lead ECGs.
2. 2023: HeartBeam withdrew the AIMI 510(k), stating in its quarterly filing that the emergency-room product addressed a significantly smaller opportunity than its ambulatory device.
3. December 16, 2024: The FDA cleared the HeartBeam System, a credit-card-sized, cable-free device that records the heart's electrical signals from three directions, for comprehensive arrhythmia assessment.
4. December 10, 2025: After HeartBeam appealed a November 2025 not-substantially-equivalent determination, the FDA cleared its software that synthesizes a 12-lead ECG from those signals, also for arrhythmia assessment.
5. October 5, 2026: The FDA granted Breakthrough Device designation for assessing possible heart attacks at home with the HeartBeam System.

The 2022 filing sought a hospital use built on existing 12-lead equipment. The October designation covers the patient-held device, used at home when symptoms begin. The 2025 clearance arrived only after HeartBeam appealed the agency's first determination.

Medicare coverage and the RAPID proposal

HeartBeam also tied the designation to payment. Breakthrough status is a prerequisite for certain expedited Medicare coverage routes, and in April 2026 CMS and the FDA proposed the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway, under which CMS would issue a proposed national coverage determination on the same day an eligible Breakthrough Device receives FDA marketing authorization. That sequence starts with an authorization, and as of October 5, 2026 HeartBeam had yet to begin the pivotal study meant to support one for heart attack assessment.

Why BEAT moved 20.10% in ten minutes

At 0.4154 before the headline, BEAT was priced under a dollar, so each one-cent change equalled 2.41% of the stock price. The full 10-minute gain to 0.4989 amounted to 8.35 cents a share. The headline crossed 59 minutes before the 9:30 a.m. ET open, in pre-market trading, where fewer orders rest at each price level than in the regular session, so a burst of buying can lift a low-priced stock by several cents at once. Most of the move came in the first minute: the 15.70% rise by the end of that minute accounts for more than three-quarters of the 10-minute gain. On the 1-minute chart, the first full bar after the headline closed at 0.4696, 13.05% above the pre-headline level, and the buying resumed after the tenth minute: twelve minutes after the headline BEAT traded at 0.5461, 31.46% above it.